Results 41 to 50 of about 46,290 (201)

Targeting IL27RA Enhances Immunotherapy in Triple‐Negative Breast Cancer by Modulating Tumor Cells and the Tumor Microenvironment

Advanced Science, EarlyView.
IL27RA upregulation drives immune evasion in TNBC by suppressing MHC‐I expression and reprogramming T/NK‐cell states, establishing an immune‐excluded tumor phenotype. Targeting this epithelial‐intrinsic IL27RA–PI3K/AKT axis offers a promising strategy to overcome immunotherapy resistance.
Jiachi Xu, Qian Long, Meirong Zhou, Qitong Chen, Jing Peng, Qingchun Liang, Danhua Zhang, Hui Zhou, Wenjun Yi   +8 more
wiley   +1 more source

Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. [PDF]

, 2017
Predictive biomarkers have the potential to facilitate cancer precision medicine by guiding the optimal choice of therapies for patients. However, clinicians are faced with an enormous volume of often-contradictory evidence regarding the therapeutic ...
Beckman, Robert A., Boca, Simina M., Brody, Jonathan R., Madhavan, Subha, Marshall, John L., Pishvaian, Michael J., Rao, Shruti, Riazi, Shahla, Yabar, Cinthya S.   +8 more
core   +1 more source

Morphometric study of myocardial changes during doxorubicin-induced cardiomyopathy in mice [PDF]

, 1988
Doxorubicin (DOX) is one of the most effective anti-cancer drugs in oncology, but may cause a cumulative dose-dependent cardiomyopathy in a number of cancer patients. The effect of DOX on the heart was studied in mice treated with i.v. injections of 2 mg/
Feijen, Jan, Mross, Klaus, Pinedo, Herbert M., Poort, Jos S.E. van der, Schlüper, Henny M.M., Velzen, Dick van, Vijgh, Wim J.F. van der   +6 more
core   +3 more sources

Biomimetic Nanomedicine for Senescence‐Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

Advanced Science, EarlyView.
A multifunctional mPDZM nanoplatform is developed in this study. mPDZM integrates chemotherapy‐induced senescence, selective senolysis, and STING‐mediated immune activation. mPDZM effectively clears senescent tumor cells, remodels the tumor immune microenvironment, and enhances antitumor T‐cell responses.
Shiji Fang, Liyun Zheng, Bin Lin, Jiale Chen, Dehai Hou, Yiming Ding, Mengzhu Han, Pan Qin, Mengyuan Wang, Xiaoju Guo, Yeyu Zhang, Gaofeng Shu, Fazong Wu, Jianfei Tu, Minjiang Chen, Zhongwei Zhao, Zhuang Liu, Jiansong Ji   +17 more
wiley   +1 more source

Xanthatin Targets CISD1 to Drive Ferroptosis and Mitophagy as a Dual Anticancer Strategy in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
Triple‐negative breast cancer has a poor prognosis. Xanthatin directly targets and degrades CISD1, triggering ferroptosis through iron dysregulation. The concurrently activated mitophagy synergistically amplifies ferroptotic cell death. Xanthatin also demonstrates potent in vivo anti‐tumor efficacy with minimal toxicity, highlighting its therapeutic ...
Qinwen Liu, Haojie Chen, Xiang Li, Jingxin Liu, Yiwen Li, Zhenyi Shi, Shenshen Guo, Qingfeng Du, Aiping Lu, Daogang Guan   +9 more
wiley   +1 more source

Current perspective - Trastuzumab [PDF]

, 2009
This article will review the available clinical data on the efficacy of trastuzumab in the treatment of both early advanced breast ...
Cameron, D.A., Hall, P.S.
core   +1 more source

EDTA‐Functionalized Nanoscale Metal–Organic Framework for Onco‐Cardiology via Radiochemotherapy Synergy and Spatiotemporally Matched Iron Chelation

Advanced Science, EarlyView.
Doxorubicin (DOX)‐induced cardiotoxicity is a major limitation to its broader clinical application, while cardioprotective interventions often risk reducing the anticancer efficacy of DOX. To address these challenges, this work constructs an EDTA‐functionalized metal–organic framework that enhances tumor therapy and provides efficient cardioprotection ...
Daojing Yuan, Liyang Tian, Luwen Zhuang, Yongyu Liang, Lingfei Chen, Xuetao Wang, Yanli Li, Xiyong Yu, Teng Gong   +8 more
wiley   +1 more source

Toxicity Analysis in the ADEBAR Trial: Sequential Anthracycline-Taxane Therapy Compared with FEC120 for the Adjuvant Treatment of High-Risk Breast Cancer [PDF]

, 2012
Background: Data from meta-analyses have shown taxane-containing therapies to be superior to anthracycline-based treatments for high-risk breast cancer. Patients and Methods: The ADEBAR trial was a multicenter phase Ill trial in which patients with lymph
Aivazova-Fuchs, Viktoria, Andergassen, Ulrich, Annecke, Katja, Augustin, Doris, Friese, Klaus, Harbeck, Nadia, Hepp, Philip, Janni, Wolfgang, Jückstock, Julia K., Kiechle, Marion, Mohrmann, Svjetlana, Rack, Brigitte, Salmen, Jessica, Schönherr, Alexandra, Simon, Wolfgang, Wischnik, Arthur, Zwingers, Thomas   +16 more
core   +1 more source

Building an Intelligent Cardiovascular System Platform: Embedding Artificial Intelligence across All Facets of Cardiovascular Medicine

Advanced Intelligent Systems, EarlyView.
This paper presents an integrated AI‐driven cardiovascular platform unifying multimodal data, predictive analytics, and real‐time monitoring. It demonstrates how artificial intelligence—from deep learning to federated learning—enables early diagnosis, precision treatment, and personalized rehabilitation across the full disease lifecycle, promoting a ...
Mowei Kong, Xingwei Zhao, Qiuting Li, Yang Yu, Chunxiang Zhang   +4 more
wiley   +1 more source

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source